High-density array-CGH with targeted NGS unmask multiple noncontiguous minute deletions on chromosome 3p21 in mesothelioma

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Proceedings of the National Academy of Sciences of the United States of America

• Publication date

  2016-11-09

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1073/pnas.1612074113PMID 27834213PMCID PMC5127333
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• SETD2: an epigenetic modifier with tumor suppressor functionality

  2016cited by this paper
• Consensus Report of the 2015 Weinman International Conference on Mesothelioma

  2016cited by this paper
• HMGB1 and Its Hyperacetylated Isoform are Sensitive and Specific Serum Biomarkers to Detect Asbestos Exposure and to Identify Mesothelioma Patients

  2016cited by this paper
• Malignant Mesothelioma: Time to Translate?

  2016cited by this paper
• Abstract LB-331: Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations

  2016cited by this paper
• Minimal asbestos exposure in germline BAP1 heterozygous mice is associated with deregulated inflammatory response and increased risk of mesothelioma

  2016cited by this paper
• Genome-based Mutational Analysis by Next Generation Sequencing in Patients with Malignant Pleural and Peritoneal Mesothelioma.

  2016cited by this paper
• Exome Aggregation Consortium

  2016cited by this paper
• Genomic disruption of the histone methyltransferase SETD2 in chronic lymphocytic leukaemia

  2016cited by this paper
• Elucidating the cancer-specific genetic alteration spectrum of glioblastoma derived cell lines from whole exome and RNA sequencing

  2015cited by this paper
• Targeted next-generation sequencing reveals high frequency of mutations in epigenetic regulators across treatment-naïve patient melanomas

  2015cited by this paper
• Not All Next Generation Sequencing Diagnostics are Created Equal: Understanding the Nuances of Solid Tumor Assay Design for Somatic Mutation Detection

  2015influential reference
• Genomic landscapes of breast fibroepithelial tumors

  2015cited by this paper
• Low PBRM1 identifies tumor progression and poor prognosis in breast cancer.

  2015cited by this paper
• Whole-exome sequencing reveals frequent genetic alterations in BAP1, NF2, CDKN2A, and CUL1 in malignant pleural mesothelioma.

  2015cited by this paper
• SETD2 histone modifier loss in aggressive GI stromal tumours

  2015cited by this paper
• Recent insights emerging from malignant mesothelioma genome sequencing.

  2015cited by this paper
• Targeted Next-Generation Sequencing of Cancer Genes in Advanced Stage Malignant Pleural Mesothelioma: A Retrospective Study

  2015cited by this paper
• Analysis of protein-coding genetic variation in 60,706 humans

  2015cited by this paper
• High Incidence of Somatic BAP1 Alterations in Sporadic Malignant Mesothelioma

  2015cited by this paper
• Combined Genetic and Genealogic Studies Uncover a Large BAP1 Cancer Syndrome Kindred Tracing Back Nine Generations to a Common Ancestor from the 1700s

  2015cited by this paper
• 50th anniversary of the Declaration of Helsinki: the double standard was introduced.

  2014cited by this paper
• BAF180 Promotes Cohesion and Prevents Genome Instability and Aneuploidy

  2014cited by this paper
• Bap1 is essential for kidney function and cooperates with Vhl in renal tumorigenesis

  2014cited by this paper
• CARMA: CARM1 methylation of SWI/SNF in breast cancer.

  2014cited by this paper
• Biallelic germline and somatic mutations in malignant mesothelioma: Multiple mutations in transcription regulators including mSWI/SNF genes

  2014cited by this paper
• BAP1 and cancer

  2013cited by this paper
• Lessons from the cancer genome.

  2013cited by this paper
• Exome sequencing identifies frequent inactivating mutations in BAP1, ARID1A and PBRM1 in intrahepatic cholangiocarcinomas

  2013cited by this paper
• Frequent inactivation of the BAP1 gene in epithelioid‐type malignant mesothelioma

  2012cited by this paper
• Molecular changes in mesothelioma with an impact on prognosis and treatment.

  2012cited by this paper
• Clinical Characteristics of Patients with Malignant Pleural Mesothelioma Harboring Somatic BAP1 Mutations

  2012cited by this paper
• Early Detection of Malignant Pleural Mesothelioma in Asbestos-Exposed Individuals with a Noninvasive Proteomics-Based Surveillance Tool

  2012cited by this paper
• Malignant mesothelioma: Facts, Myths, and Hypotheses

  2012cited by this paper
• Germline BAP1 mutations predispose to malignant mesothelioma

  2011cited by this paper
• Frequent deletion of 3p21.1 region carrying semaphorin 3G and aberrant expression of the genes participating in semaphorin signaling in the epithelioid type of malignant mesothelioma cells.

  2011cited by this paper
• The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma

  2011cited by this paper
• Cancer: When catastrophe strikes a cell

  2011cited by this paper
• Identification of a core member of the SWI/SNF complex, BAF155/SMARCC1, as a human tumor suppressor gene

  2011cited by this paper
• Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma

  2010cited by this paper
• Genomic events associated with progression of pleural malignant mesothelioma

  2009cited by this paper
• Systematic sequencing of renal carcinoma reveals inactivation of histone modifying genes

  2009cited by this paper
• Evaluation of the 3p21.3 tumour-suppressor gene cluster

  2007cited by this paper
• Genomic profiling of malignant pleural mesothelioma with array‐based comparative genomic hybridization shows frequent non‐random chromosomal alteration regions including JUN amplification on 1p32

  2007cited by this paper
• Gene copy number analysis in malignant pleural mesothelioma using oligonucleotide array CGH

  2007cited by this paper
• Molecular pathogenesis of malignant mesothelioma and its relationship to simian virus 40.

  2003cited by this paper
• Simian virus 40: the link with human malignant mesothelioma is well established.

  2000cited by this paper
• Loss of heterozygosity on the short arm of chromosome 3 in mesothelioma cell lines and solid tumors

  1994cited by this paper
• Recurrent deletions of specific chromosomal sites in 1p, 3p, 6q, and 9p in human malignant mesothelioma.

  1993cited by this paper

• Moving Beyond Morphology: Toward a Morpho-Molecular Classification of Pleural Mesothelioma.

  2026cites this paper
• Advances in the Basic Sciences in Thoracic Oncology in the Last 20 Years and Their Translational Impact.

  2026cites this paper
• An overview of BAP1 biological functions and current therapeutics.

  2025cites this paper
• Molecular Determinants of Immunotherapy Efficacy in Mesothelioma: A Step Toward Precision Oncology.

  2025cites this paper
• Molecular and Immunohistochemical Testing in Mesothelioma and Other Mesothelial Lesions.

  2024cites this paper
• Comparison of Immunohistochemistry, Next-generation Sequencing and Fluorescence In Situ Hybridization for Detection of MTAP Loss in Pleural Mesothelioma

  2024cites this paper
• Biomarkers to predict the benefits of immune‑checkpoint blockade‑based therapy in patients with malignant peritoneal mesothelioma (Review)

  2024cites this paper
• Mesothelioma Cases in the World Trade Center Survivors.

  2024cites this paper
• Individualized Cell-Free DNA Monitoring With Chromosomal Junctions for Mesothelioma

  2024cites this paper
• The genetic susceptibility in the development of malignant pleural mesothelioma: somatic and germline variants, clinicopathological features and implication in practical medical/surgical care: a narrative review

  2024cites this paper
• Complex Genomic Rearrangement Patterns in Malignant Pleural Mesothelioma due to Environmental Asbestos Exposure.

  2024cites this paper
• Whole-Genome Comparative Copy Number Alteration Profiling between Malignant Pleural Mesothelioma and Asbestos-Induced Chronic Pleuritis.

  2024cites this paper
• Diffuse Pleural Mesothelioma: Advances in Molecular Pathogenesis, Diagnosis and Treatment.

  2023cites this paper
• BAP1 is a novel regulator of HIF-1α

  2023cites this paper
• CAMK2D: a novel molecular target for BAP1-deficient malignant mesothelioma

  2023cites this paper
• Expanded detection and impact of BAP1 alterations in cancer

  2023cites this paper
• Important functional role of the protein osteopontin in the progression of malignant pleural mesothelioma

  2023cites this paper
• SETDB1 tumour suppressor roles in near-haploid mesothelioma involve TP53

  2023cites this paper
• Pleural Mesothelioma: Treatable Traits of a Heterogeneous Disease

  2023cites this paper
• BAP1 as a guardian of genome stability: implications in human cancer

  2023cites this paper
• New pathogenic germline variants identified in mesothelioma.

  2023cites this paper
• Genomic profiling of tissue and blood predicts survival outcomes in patients with resected pleural mesothelioma.

  2023cites this paper
• Preventive and therapeutic opportunities: targeting BAP1 and/or HMGB1 pathways to diminish the burden of mesothelioma

  2023cites this paper
• Novel Therapeutic Targets and Immune Dysfunction in Malignant Pleural Mesothelioma

  2022cites this paper
• BAP1 loss induces mitotic defects in mesothelioma cells through BRCA1-dependent and independent mechanisms

  2022cites this paper
• Diagnostics of BAP1-Tumor Predisposition Syndrome by a Multitesting Approach: A Ten-Year-Long Experience

  2022cites this paper
• Mesothelioma Mouse Models with Mixed Genomic States of Chromosome and Microsatellite Instability

  2022cites this paper
• DNA methylation-based machine learning classification distinguishes pleural mesothelioma from chronic pleuritis, pleural carcinosis, and pleomorphic lung carcinomas.

  2022cites this paper
• Myxoid pleomorphic liposarcoma is distinguished from other liposarcomas by widespread loss of heterozygosity and significantly worse overall survival: a genomic and clinicopathologic study

  2022cites this paper
• BAP1 loss by immunohistochemistry predicts improved survival to first line platinum/pemetrexed chemotherapy for pleural mesothelioma patients: A validation study.

  2022cites this paper
• Medical and surgical care of mesothelioma patients and their relatives carrying germline BAP1 mutations.

  2022cites this paper
• Unravelling the tumour genome: The evolutionary and clinical impacts of structural variants in tumourigenesis

  2022cites this paper
• Establishment and validation of a novel immune-related prognostic signature in malignant pleural mesothelioma

  2022cites this paper
• Malignant pleural mesothelioma with an EML4-ALK fusion: Expect the unexpected!

  2022cites this paper
• New Era for Malignant Pleural Mesothelioma: Updates on Therapeutic Options.

  2022cites this paper
• Roles of the BAP1 Tumor Suppressor in Cell Metabolism

  2021cites this paper
• Clonal architecture in mesothelioma is prognostic and shapes the tumour microenvironment

  2021cites this paper
• Asbestos‐induced mesothelial injury and carcinogenesis: Involvement of iron and reactive oxygen species

  2021cites this paper
• Malignant pleural mesothelioma: an update

  2021influential citation
• BAP1 forms a trimer with HMGB1 and HDAC1 that modulates gene × environment interaction with asbestos

  2021cites this paper
• BRCA-associated protein 1 (BAP1) and miR-31 combination predicts outcomes in epithelioid malignant pleural mesothelioma

  2021cites this paper
• Pre-Clinical Research Advancements Relating to Improving the Diagnosis and Treatment of Malignant Pleural Mesothelioma: A Review

  2021cites this paper
• Risk prediction for metastasis of clear cell renal cell carcinoma using digital multiplex ligation‐dependent probe amplification

  2021cites this paper
• The efficacy of immune checkpoint inhibitors in thoracic malignancies

  2021cites this paper
• Matter of TIME: the tumor-immune microenvironment of mesothelioma and implications for checkpoint blockade efficacy

  2021cites this paper
• Immunotherapy in malignant pleural mesothelioma: a review of literature data

  2021cites this paper
• Multi-site tumor sampling highlights molecular intra-tumor heterogeneity in malignant pleural mesothelioma

  2021cites this paper
• Immune checkpoint inhibitors a new player in the therapeutic game of mesothelioma: New reality with new challenges.

  2021cites this paper
• Immune checkpoint inhibitors for unresectable malignant pleural mesothelioma

  2021cites this paper
• Recent Advances in the Genomic and Proteomic Researches on Mesothelioma: What Are Novel Insights into Mesothelioma Biology?

  2021cites this paper
• Roles and mechanisms of BAP1 deubiquitinase in tumor suppression

  2021cites this paper
• Genetic Predisposition to Mesothelioma: What Are the Biological Mechanisms and What Are the Clinical Characteristics of These Mesotheliomas?

  2021cites this paper
• Wedding of Molecular Alterations and Immune Checkpoint Blockade: Genomics as a Matchmaker.

  2021cites this paper
• Asbestos and Zeolites: from A to Z via a Common Ion.

  2021cites this paper
• BAP1 and miR-31 combination predicts outcomes in epithelioid malignant pleural mesothelioma

  2021cites this paper
• Alterations in BAP1 Are Associated with Cisplatin Resistance through Inhibition of Apoptosis in Malignant Pleural Mesothelioma

  2021influential citation
• Malignant mesothelioma metastatic to the oral region and latest topics (Review).

  2020cites this paper
• Combined MEK and PI3K/p110b inhibition as a novel targeted therapy for malignant mesothelioma displaying sarcomatoid features.

  2020cites this paper
• FREQUENT HOMOZYGOUS DELETIONS OF TYPE I INTERFERON GENES IN PLEURAL MESOTHELIOMA CONFER SENSITIVITY TO ONCOLYTIC MEASLES VIRUS.

  2020cites this paper
• The Tumor Suppressor BAP1 Regulates the Hippo Pathway in Pancreatic Ductal Adenocarcinoma

  2020cites this paper
• Immunotherapy in Malignant Pleural Mesothelioma

  2020cites this paper
• Genetic alterations of malignant pleural mesothelioma: association with tumor heterogeneity and overall survival

  2020cites this paper
• Current evidence and future perspectives of immune-checkpoint inhibitors in unresectable malignant pleural mesothelioma

  2020cites this paper
• Emerging Treatments for Malignant Pleural Mesothelioma: Where Are We Heading?

  2020cites this paper
• Mesothelioma developing in carriers of inherited genetic mutations

  2020cites this paper
• Chromosomal rearrangements and their neoantigenic potential in mesothelioma

  2020cites this paper
• How asbestos and other fibers cause mesothelioma

  2020cites this paper
• Mth1 deficiency provides longer survival upon intraperitoneal crocidolite injection in female mice

  2020cites this paper
• The Biology of Malignant Mesothelioma and the Relevance of Preclinical Models

  2020cites this paper
• Malignant Pleural Mesothelioma: Genetic and Microenviromental Heterogeneity as an Unexpected Reading Frame and Therapeutic Challenge

  2020cites this paper
• Tumour predisposition and cancer syndromes as models to study gene–environment interactions

  2020cites this paper
• Biological Mechanisms and Clinical Significance of BAP1 Mutations in Human Cancer.

  2020influential citation
• Evolution of Genomic and T-cell Repertoire Heterogeneity of Malignant Pleural Mesothelioma Under Dasatinib Treatment

  2020cites this paper
• Is DNA repair a potential target for effective therapies against malignant mesothelioma?

  2020cites this paper
• Immunotherapy for mesothelioma: rationale and new approaches.

  2020cites this paper
• Pathology of Malignant Pleural Mesothelioma.

  2020cites this paper
• RNA editing in mesothelioma: a look forward

  2020cites this paper
• The Correlations between CXCL12, CXCR4, EAAT1 and GS in Malignant Pleural Mesothelioma, and CXCL12 Regulates Cell Invasion and Migration via CXCR4/EAAT1/GS Pathway

  2020cites this paper
• Biomarkers in the diagnosis and treatment of malignant pleural disease: an integrative review

  2020cites this paper
• Long non-coding RNA expression profiles and related regulatory networks in areca nut chewing-induced tongue squamous cell carcinoma.

  2020cites this paper
• Emerging Drug Therapies for Mesothelioma

  2020cites this paper
• Identification of cancer drivers, conserved alteration patterns and evolutionary trajectories in tumors

  2020cites this paper
• Identification of CD24 as a potential diagnostic and therapeutic target for malignant pleural mesothelioma

  2020cites this paper
• Epigenetic Alterations and Biomarkers for Immune Checkpoint Inhibitors–Current Standards and Future Perspectives in Malignant Pleural Mesothelioma Treatment

  2020cites this paper
• Tumeurs rares : immunothérapies

  2020cites this paper
• Malignant Mesothelioma: Mechanism of Carcinogenesis

  2020cites this paper
• Malignant Mesothelioma: Molecular Markers

  2020cites this paper
• BAP1 promotes stalled fork restart and cell survival via INO80 in response to replication stress.

  2019cites this paper
• Fluorescence in situ hybridization (FISH) provides estimates of minute and interstitial BAP1, CDKN2A, and NF2 gene deletions in peritoneal mesothelioma

  2019cites this paper
• Copy number variations in candidate genomic regions confirm genetic heterogeneity and parental bias in Hirschsprung disease

  2019cites this paper
• Analysis of CCDC6 as a novel biomarker for the clinical use of PARP1 inhibitors in malignant pleural mesothelioma.

  2019cites this paper
• BAP1 haploinsufficiency predicts a distinct immunogenic class of malignant peritoneal mesothelioma

  2019cites this paper
• BAP1 Status Determines the Sensitivity of Malignant Mesothelioma Cells to Gemcitabine Treatment

  2019cites this paper
• Does Chromothripsis Make Mesothelioma an Immunogenic Cancer?

  2019cites this paper
• Panorama epigenético del mesotelioma pleural maligno

  2019cites this paper
• Mesothelioma: Scientific clues for prevention, diagnosis, and therapy

  2019cites this paper
• Pathologic considerations and standardization in mesothelioma clinical trials.

  2019cites this paper
• BAP1 in solid tumors.

  2019cites this paper
• Neoantigenic Potential of Complex Chromosomal Rearrangements in Mesothelioma

  2019cites this paper
• Well-Differentiated Papillary Mesothelioma of the Peritoneum Is Genetically Distinct from Malignant Mesothelioma

  2019cites this paper